Page last updated: 2024-10-24

cgp 12177 and Down Syndrome

cgp 12177 has been researched along with Down Syndrome in 1 studies

CGP 12177 : A benzimidazole that is benzimidazol-2-one substituted at position 4 by a 3-(tert-butylamino)-2-hydroxypropoxy group.

Down Syndrome: A chromosome disorder associated either with an extra chromosome 21 or an effective trisomy for chromosome 21. Clinical manifestations include hypotonia, short stature, brachycephaly, upslanting palpebral fissures, epicanthus, Brushfield spots on the iris, protruding tongue, small ears, short, broad hands, fifth finger clinodactyly, Simian crease, and moderate to severe INTELLECTUAL DISABILITY. Cardiac and gastrointestinal malformations, a marked increase in the incidence of LEUKEMIA, and the early onset of ALZHEIMER DISEASE are also associated with this condition. Pathologic features include the development of NEUROFIBRILLARY TANGLES in neurons and the deposition of AMYLOID BETA-PROTEIN, similar to the pathology of ALZHEIMER DISEASE. (Menkes, Textbook of Child Neurology, 5th ed, p213)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Dierssen, M1
Vallina, IF1
Baamonde, C1
García-Calatayud, S1
Lumbreras, MA1
Flórez, J1

Other Studies

1 other study available for cgp 12177 and Down Syndrome

ArticleYear
Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome.
    Brain research, 1997, Feb-28, Volume: 749, Issue:2

    Topics: 1-Methyl-3-isobutylxanthine; Adrenergic beta-Agonists; Animals; Brain; Cell Membrane; Cerebellum; Ce

1997